Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've had this stock since the Google buyout hoax of 2012. I was up around $500 when the hoax was debunked. Couldn't get out. https://www.google.com/amp/business.financialpost.com/fp-tech-desk/icoa-chief-says-company-never-had-google-buyout-talks-press-release-was-hoax/amp?client=safari
Tweet:"That's one small step for man, one GIANT leap for NECA. Details soon."
Sorry man! Focus on being the best dad you can! Praying for you!
Here we go again :(
Interpace Diagnostics Announces Proposed Public Offering of Common Stock
Source: PR Newswire (US)
PARSIPPANY, N.J., Feb. 2, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)("Interpace" or the "Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. The Company intends to use the net proceeds of the offering for working capital, repayment of indebtedness and other liabilities, and general corporate purposes.
Maxim Group LLC is acting as sole book-running manager for the offering.
The shares of common stock described above are being offered under the Company's shelf registration statement on Form S-3 (No. 333-207263), including a base prospectus, previously filed with and declared effective by the U.S. Securities and Exchange Commission ("SEC"). The shares will be offered by means of a prospectus supplement and accompanying prospectus, forming a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the website of the SEC at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement and accompanying prospectus, when available, also may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at 212-895-3745. Before you invest, you should carefully read the preliminary prospectus supplement and the accompanying prospectus in that registration statement and other documents Interpace has filed or will file with the SEC for more complete information about Interpace and the offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Interpace Diagnostics Group, Inc.
Interpace provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests: PancraGen®, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace's mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.
FORWARD-LOOKING STATEMENTS:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the Company's ability to adequately finance the business, its ability to restructure its debt and other obligations, the market's acceptance of its molecular diagnostic tests, its ability to secure additional business and generate higher profit margins through sales of its molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments and our ability to maintain our NASDAQ listing. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in the Company's filings with the SEC, including without limitation, the Annual Report on Form 10-K filed with the SEC on March 30, 2016, as amended on April 29, 2016 and June 14, 2016, and the Quarterly Report on Form 10-Q filed with the SEC on November 17, 2016. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
CONTACTS:
Victor Roberts
RedChip Companies
407.644.4256, ext. 111
victor@redchip.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/interpace-diagnostics-announces-proposed-public-offering-of-common-stock-300401606.html
SOURCE Interpace Diagnostics Group, Inc.
Copyright 2017 PR Newswire
Beautifull!!!!
Woo Hoo!!!!
Very nice! Have a great evening! This could be a big month!
$2.98 AH!! Go IPCI!!
Bid building today at $2.50!!
Wow! Nice buy!
Ok like that $4.99 on ask as well! Lets move on up!!
I love these low floaters!! :)
Looking even better today! Bid has been creeping up each day!
Bid moving up!!
I've got my harness, lets go!!!!
BHGI!!!!!
Looking forward to the new year! Happy New Year BHGI faithfuls!!!!
Merry Christmas Friends!!
Merry Christmas Friends!!
Merry Christmas Friends!!
Merry Christmas Friends!! Here's to a prosperous new year here!!
Merry Christmas Friends!!
Each time I raise my bid the algorithm automatically leap frogs me with a 400 share bid.
I can feel it!! It's coming!!
I only have a million but I've had them since April of 2014! Is something finally up?
Yes buy my shares!!!
So ready for us to score! I can feel it!
What a wonderful surprise to Wake up to a E*TRADE notification: "IPCI is in play!" Happy Black Friday! Glad to be in the black with my shares!
Nice! Spot on!
Man why didn't they buy my shares? I've been stuck here too long...
A November to Remember?
Our largest volume day since we added the "d". Wonder why? Hmmm...
Tick Tock...
Looking good!
Thanks, I forgot about that.
I wish quotes would show properly on this! I have no realtime source that is accurate on this yet.
I wondered the same thing!